Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
1. A method for delivering adalimumab into a wall of a gastrointestinal tract, comprising:
swallowing a drug delivery device comprising a capsule, an actuator having a first configuration and a second configuration, and a solid adalimumab preparation operably coupled to the actuator, the solid adalimumab preparation comprising a therapeutically effective dose of adalimumab, the solid adalimumab preparation being contained within the capsule in the first configuration and advanced into the wall of the gastrointestinal tract in the second configuration, wherein the solid adalimumab preparation has a shape configured for penetration of the wall of the gastrointestinal tract.
2. The method of claim 1 , wherein the dose of adalimumab treats an autoimmune disorder selected from the group consisting of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, plaque psoriasis, and ulcerative colitis.
3. The method of claim 1 , wherein a weight percent of adalimumab in the preparation comprises between 8 to 12%.
4. The method of claim 1 , wherein the dose of adalimumab in the preparation is in a range of 1 to 5 mg.
5. The method of claim 1 , wherein the adalimumab preparation comprises at least one pharmaceutical excipient.
6. The method of claim 1 , wherein the solid adalimumab preparation advanced into the wall of the gastrointestinal tract is retained within the wall of the gastrointestinal wall to release the dose of adalimumab therein.
7. The method of claim 1 , wherein the t½ of the adalimumab advanced into the wall of the gastrointestinal tract is greater than the t½ for orally ingested adalimumab that is not advanced into the wall of the gastrointestinal tract.
8. A method for delivering adalimumab into a wall of a gastrointestinal tract, comprising:
providing a drug delivery device to comprise a capsule, an actuator having a first configuration and a second configuration, and a solid adalimumab preparation operably coupled to the actuator, the solid adalimumab preparation comprising a therapeutically effective dose of adalimumab, the solid adalimumab preparation being contained within the capsule in the first configuration and advanced into the wall of the gastrointestinal tract in the second configuration, wherein the solid adalimumab preparation has a shape configured for penetration of the wall of the gastrointestinal tract; and
providing instructions for the ingestible device to be swallowed by a patient.
9. The method of claim 8 , wherein the dose of adalimumab treats an autoimmune disorder selected from the group consisting of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, plaque psoriasis, and ulcerative colitis.
10. The method of claim 8 , wherein a weight percent of adalimumab in the preparation comprises between 8 to 12%.
11. The method of claim 8 , wherein the dose of adalimumab in the preparation is in a range of 1 to 5 mg.
12. The method of claim 8 , wherein the adalimumab preparation comprises at least one pharmaceutical excipient.
13. The method of claim 8 , wherein the solid adalimumab preparation advanced into the wall of the gastrointestinal tract is retained within the wall of the gastrointestinal wall to release the dose of adalimumab therein.
14. The method of claim 8 , wherein the t½ of the adalimumab advanced into the wall of the gastrointestinal tract is greater than the t½ for orally ingested adalimumab that is not advanced into the wall of the gastrointestinal tract.
15. A method, comprising:
administering a swallowable capsule containing an actuator having a first configuration and a second configuration, and a solid adalimumab preparation that (i) comprises a therapeutically effective dose of adalimumab, (ii) is operably coupled to the actuator, and (iii) is contained within the capsule in the first configuration and is advanced into a wall of the gastrointestinal tract in the second configuration.
16. The method of claim 15 , wherein the dose of adalimumab treats an autoimmune disorder selected from the group consisting of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, plaque psoriasis, and ulcerative colitis.
17. The method of claim 15 , wherein a weight percent of adalimumab in the preparation comprises between 8 to 12%.
18. The method of claim 15 , wherein the dose of adalimumab in the preparation is in a range of 1 to 5 mg.
19. The method of claim 16 , wherein the adalimumab preparation comprises at least one pharmaceutical excipient.
20. The method of claim 15 , wherein the solid adalimumab preparation advanced into the wall of the gastrointestinal tract is retained within the wall of the gastrointestinal wall to release the dose of adalimumab therein.
21. The method of claim 15 , wherein the t½ of the adalimumab advanced into the wall of the gastrointestinal tract is greater than the t½ for orally ingested adalimumab that is not advanced into the wall of the gastrointestinal tract.